Abiopharma

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Oramed and Lifeward Announce Strategic Transaction

(70% Positive) Dentsply Sirona Inc (XRAY) Files Form 8-K

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

(99% Neutral) Amneal Pharmaceuticals Inc. (AMRX) Reports Q1 2026 Financial Results

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated <em>Staphylococcus aureus</em> Bacteremia

/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

XTL Biopharmaceuticals Acquires 85% of Beyond Airs Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease